Roche Diagnostics Partners with Nordic Bioscience for Endotrophin Research Development

Collaboration in Cardiovascular Research



Roche Diagnostics has partnered with Nordic Bioscience to advance the understanding of Endotrophin, a critical biomarker in the analysis of various health conditions, particularly related to cardiovascular risks. On November 17, 2026, Nordic Bioscience proudly announced that Roche Diagnostics has made its Endotrophin (ETP) research prototype test available on the cobas® e801 analyzer within the CLIA lab of Nordic Bioscience.

Understanding Endotrophin



Endotrophin is a 77-amino acid hormone released during the formation of type VI collagen, playing a significant role in fibrosis and inflammation associated with various diseases. It has been linked to adverse outcomes in cardiovascular, renal, and metabolic disorders, making its measurement essential for understanding those at risk and for enhancing patient outcomes.

The newly introduced Endotrophin assay is a sophisticated sandwich immunoassay that quantifies this biomarker. This test is part of an ongoing collaboration between Roche Diagnostics and Nordic Bioscience, following the earlier launch of the Elecsys® PRO-C3 test, which has been certified as a CE-marked product.

Clinical Insights and Applications



Over 50,000 patients with cardiorenal metabolic syndrome have had their Endotrophin levels measured, with higher concentrations correlating with increased mortality and complications related to heart failure, particularly in those with preserved ejection fraction (HFpEF). The FDA has recognized this relationship and provided support for further investigations into the use of Endotrophin as an enrichment tool in clinical trials centered around HFpEF.

Furthermore, Endotrophin not only attends to the fibroinflammatory risk beyond traditional biomarkers like PREVENT and NT-proBNP but is also indicative of kidney function. Patients suffering from chronic kidney disease displayed significantly elevated levels of Endotrophin, which were predictive of decreasing eGFR over time.

Scientific Inquiry on Endotrophin
Research extends beyond mere observation, as Mendelian randomization studies have causally linked Endotrophin to coronary heart disease. Animal models lacking Endotrophin have shown resistance to renal fibrosis and loss of kidney function. It is also critical to note that the CD44 receptor has been identified for Endotrophin, thereby providing a target for potential therapeutic interventions.

Looking Ahead



Morten Karsdal, the CEO of Nordic Bioscience, emphasizes the importance of Endotrophin, stating, "Endotropin could be the ultimate biomarker for the cardio-renal syndrome – but importantly, it is more than just a biomarker. It's a target that requires treatment. We foresee a new narrative surrounding TNF-alpha."

This innovation represents a substantial leap in biomarker research and presents an opportunity to improve patient outcomes significantly. As Nordic Bioscience continues to integrate its unique Neoepitope platform technology with its experience, the potential for future discoveries and applications remains promising. For more insights on the ongoing research and developments at Nordic Bioscience, visit their official website.

Conclusion



The collaboration between Roche Diagnostics and Nordic Bioscience marks an important moment in the realm of cardiovascular research. By bringing the Endotrophin research prototype test to the forefront, it sets a foundation for advanced diagnostic measures that could transform patient care and management of chronic diseases. Through the continuous study and application of biomarkers like Endotrophin, the medical community is equipped to tackle some of today's most pressing health challenges.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.